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Abstract: Over the last years CFTR (cystic fibrosis transmembrane conductance regulator) modulators
have shown the ability to improve relevant clinical outcomes in patients with cystic fibrosis (CF).
This review aims at a systematic research of the current evidence on efficacy and tolerability of
CFTR modulators for different genetic subsets of patients with CF. Two investigators independently
performed the search on PubMed and included phase 2 and 3 clinical trials published in the study
period 1 January 2005–31 January 2020. A final pool of 23 papers was included in the systematic review
for a total of 4219 patients. For each paper data of interest were extracted and reported in table. In terms
of lung function, patients who had the most beneficial effects from CFTR modulation were those
patients with one gating mutation receiving IVA (ivacaftor) and patients with p.Phe508del mutation,
both homozygous and heterozygous, receiving ELX/TEZ/IVA (elexacaftor/tezacaftor/ivacaftor) had
the most relevant beneficial effects in term of lung function, pulmonary exacerbation decrease, and
symptom improvement. CFTR modulators showed an overall favorable safety profile. Next steps
should aim to systematize our comprehension of scientific data of efficacy and safety coming from
real life observational studies.
Keywords: CFTR modulators; clinical efficacy; safety; cystic fibrosis
1. Introduction
1.1. Cystic Fibrosis and the CFTR Protein
Cystic fibrosis (CF), the most common autosomal recessive disease in Caucasian populations,
is a life-limiting condition, with respiratory failure secondary to end-stage lung disease accounting as
the main cause of mortality. Early diagnosis through newborn screening, multi-professional care in
dedicated centers, advancements in strategies of treatment, and availability of therapies have gradually
improved median predicted survival up to 50 years [1].
CF is caused by mutations in the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR)
gene, first described together with its protein product in 1989 [2,3]. CFTR encodes a low conductance
cAMP-dependent chloride channel located at the apical membrane of epithelial cells in several tissues
including airways, the gastro-intestinal tract, sweat glands, and the male reproductive tract [4].
The protein includes two transmembrane domains (TMD1 and TMD2), two nucleotide-binding
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domains (NBD1 and NBD2), and a regulatory domain (RD). TMD1 and TMD2 run through the
cell membrane lipid bi-layer and combine to form the channel; each unit is formed by six distinct
segments and three extracellular loops, that undergo a coordinated folding process to reach the correct
three-dimensional stability. The RD presents sites for phosphorylation by both protein kinase C (PKC)
and A (PKA). Once the RD is phosphorylated, two ATP molecules bind to the NBD1 and NBD2
heterodimers and the channel opens, enabling anion conductance through the pore [5]. More than 2000
CFTR sequence variations have been identified, but in only a few hundred a clear association with loss
of function and clinical manifestations consistent with a diagnosis of CF has been demonstrated. These
variants are called CF-causing mutations (www.cftr2.org).
1.2. A Classification for CFTR Mutations
CFTR mutations are usually grouped according to their molecular mechanisms of dysfunction [6,7].
Class I includes mutations affecting protein synthesis, mostly represented by nonsense mutations
resulting in a premature stop codon and in mRNA decay.
Class II mutations operate mainly on trafficking and include p.Phe508del, the most prevalent
pathogenic sequence variation in Western countries, that originates from the loss of a single
phenylalanine at the 508th position in the protein sequence. The protein is incorrectly folded
and rapidly degraded, which impairs protein trafficking to the cell surface and results in severe
reduction of CFTR activity.
Class III mutations, the so-called gating mutations, diminish the open probability of the channel:
the gate-open probability of p.Gly551Asp, the most prevalent gating mutation, is more than 100-fold
lower than wild-type.
Class IV mutations, of which a frequent example is p.Arg117His, reduce chloride and bicarbonate
flow through the channel, but still permit a degree of residual function.
Class V mutations decrease amount and activity of CFTR at the cell surface, mainly through
alternative splicing that generates both normal and aberrant mRNA and functional protein.
The proportion of normal and aberrant protein might vary among patients and among different
organs in the same patient.
Class VI mutations affect CFTR stability at the plasma membrane level, thus reducing the protein
expression and recycling at the apical surface.
Sequence variations that result in limited but not absent CFTR function, that is classes IV-VI, are
called ‘residual function’ mutations.
Frequently, mutations feature more than one mechanism of protein failure and thus belong to
more than one class. A typical example is p.Phe508del, which results not only in trafficking defect
(class II) but also in reduced activity (class III) and stability at the plasma membrane level (class VI).
Although this functional classification has proven only partially useful to predict individual clinical
outcomes, it has been successfully used for new approaches in translational research.
1.3. Drug Development
CFTR function may be partially rescued by molecules known as modulators, which include
potentiators (ivacaftor), that increase conductance of the CFTR channel, and correctors (lumacaftor,
tezacaftor, elexacaftor), that improve CFTR trafficking to the cell surface.
Ivacaftor (IVA) was the first of these molecules that proved effective in a phase III clinical trial,
with significant pulmonary and nutritional improvements, and paved the way to a new generation of
precision medicine drugs in CF [8]. In 2015 the North American and European regulatory agencies
licensed a combination of ivacaftor and lumacaftor (LUM), the latter being a corrector of p.Phe508del
folding and trafficking defect. In spite of a modest improvement of lung function and other clinical
outcomes, this association had the merit to target for the first time the most common CFTR mutation
and widen the population treatable with modulators [9].
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Following the increased knowledge on the functioning of CFTR modulators and the development
of alternative experimental models, new compounds have been experimented. For patients with
p.Phe508del and a residual function mutation in trans, treatment with tezacaftor/ivacaftor (TEZ/IVA)
was effective in terms of lung function and resulted in a significantly lower rate of pulmonary
exacerbations than placebo [10].
However, neither of these double combinations was found to be satisfactorily effective in patients
carrying a single p.Phe508del and a second CFTR mutation that does not respond to previous CFTR
modulator therapy and so-called ‘minimal function’ mutations. VX-659 and VX-445 (elexacaftor, ELX)
are next-generation correctors with different mechanisms of action than previous generation correctors
LUM and TEZ.
Co-treatment with two complementary correctors proved to be the most effective strategy to
improve the expression of corrected p.Phe508del CFTR protein at the cell surface on the basis of both
in vitro activity and clinical results [11,12]. ELX and TEZ, along with IVA, has recently extended the
treated population also to those with a CFTR minimal function mutation [13]. In addition, both TEZ/IVA
and ELX/TEZ/IVA showed better results than LUM/IVA in p.Phe508del homozygous patients [14,15].
This review aims at a systematic research of the current evidence on efficacy and tolerability of
CFTR modulators nowadays available for different genetic subsets of patients with CF.
2. Methods
2.1. Search Methodology
This systematic revision was conducted according to the PRISMA statement [16]. Two investigators
(AG and MC) independently performed the research on PubMed and screened the literature in order to
identify phase 2 and 3 studies published in the study period 1 January 2005–31 January 2020. Key phrases
included ‘cystic fibrosis’ or ‘CFTR’ and ‘clinical trial’; ‘cystic fibrosis AND modulators’. The research
was extended also to other databases (EMBASE, Cochrane Central Register for Controlled Trials,
Cochrane Database of Systematic Reviews). In order to increase the search sensitivity, the reference
lists of the selected papers were assessed also manually. Non peer-reviewed papers were not selected
due to poor methodological reliability.
2.2. Study Selection
After literature search, two independent investigators reviewed titles and abstracts in order to
select those that fulfilled the study criteria; in case of disparity, a final decision was taken by a third
reviewer (SA). The authors included only phase 2 and 3 clinical trials published in the mentioned
study period. In accordance with the inclusion criteria mentioned above, literature on new modulators
dealing with in vitro and preclinical data as well as phase 1 clinical trials, although of interest, was
excluded. Phase 2 trials that have been completed with results but not yet undergone the peer-review
process and publication were excluded from the systematic analysis. Articles were also excluded
if (1) written in languages other than English; (2) they were abstracts presented in national and
international congresses; (3) they were commentaries, correspondences, editorials, case-series. The full
text was obtained for selected papers.
2.3. Data Extraction
Data of interest were extracted from each included paper. Qualitative and quantitative data
were extracted by the same reviewers (AG and MC) who performed the study selection, with the
help of a third reviewer (SA) if needed. Data of interest included name of the first author, year of
publication, phase of study, study population and sample size, type of intervention, duration, primary
and secondary endpoints, report of adverse events (AEs), and number of patients who interrupted the
study drug due to the occurrence of any AE. Corresponding authors were contacted if data were unclear
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or not reported in the full text. In consideration of the heterogeneity of the papers, a meta-analysis was
not performed.
3. Results
3.1. Study Selection and Characteristics
Figure 1 shows the selection process and the search results. Qualitative reviews, retrospective
analysis, and in vitro experiments were rejected. A pool of 23 studies was included in the systematic
review with a total of 4219 (age 6–11: 436; age 12+: 3783) patients. The papers selected were published
between the years 2005 and 2020. We included 11 phase 2 and 12 phase 3 clinical trials. Characteristics
of selected clinical trials are reported in Table 1.
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Table 1. Results of the systematic review.
Author, Year Phase Study Population Arms Duration Results(1 = Primary Outcome; 2 = Key Secondary Outcomes)
Patients Who Interrupted the
Study Drug Due to AEs
Accurso, 2010 [17] 2
CFTR: at least one G551D
Age: 18+
Sample size: 20 (first part)
and 19 (second part)
First part
IVA 25 mg BID
IVA 75 mg BID
IVA 150 mg BID
Placebo
Second part
IVA 150 mg BID
IVA 250 mg BID
Placebo
First part
Two 14 day periods
Second part
28 days
(1) The frequency of adverse events was similar between the groups
At day 28 in IVA 150 mg group:
(2) NPD: −3.5 mV (−8.3, −0.5)
(2) ST: −59.2 mmol/L (−66, −19)
(2) FEV1: 8.7% (2.3, 31.3)
(2) CFQ-R: 8.3 (0, 16.7)
No discontinuations due to AEs
Ramsey, 2011 [8] 3
CFTR: at least one G551D
Age: 12+
Sample size: 161
IVA 150 mg BID
Placebo 48 weeks
(1) absolute change in ppFEV1 (week 24): 10.6%
(2) PEx decrease (week 48): −55%
(2) CFQ-R: +8.6 points
(2) BMI: +2.7 kg
(2) ST: −48.1 mmol/L
One patient discontinued the
study drug for increased LFTs
(0.6%)
Flume, 2012 [18] 2
CFTR: F/F
Age: 12+
Sample size: 140
IVA 150 mg BID
Placebo 16 weeks
(1) absolute change in ppFEV1: 1.7% (−0.6, 4.1)
(2) ST: -2.9 (-5.6, -0.2)
(2) BMI: no significant change
(2) CFQ-R: no significant change
No discontinuations due to AEs
Clancy, 2012 [19] 2
CFTR: F/F
Age: 18+
Sample size: 89
LUM 25 mg SID
LUM 50 mg SID
LUM 100 mg SID
LUM 200 mg SID
Placebo
28 days
(1) safety: no difference in AEs between groups
(2) ST: −6.6 (−10.27, −2.83)
(2) NPD: no significant change
Four patients discontinued the
study drug (respiratory AEs)
Davies, 2013 [20] 3
CFTR: at least one G551D
Age: 6–11
Sample size: 52
IVA 150 mg BID
Placebo 48 weeks
(1) absolute change in ppFEV1 through week 24: 12.5 (6.6, 18.3)
(2) absolute change in ppFEV1 through week 48: 10 (4.5, 15.5)
(2) weight at weeks 24 and 48: 1.9 (0.9, 2.9) and 2.8 (1.3, 4.2)
(2) ST through weeks 24 and 48: −54.3 (−61.8, −46.8); −53.5 (−60.9, -46)
(2) CFQ-R through weeks 24 and 48: 6.1 (−1.4, 13.5); 5.1 (−1.6, 11.8)
(2) safety: no difference in AEs between groups
One patient discontinued the
study drug (1.9%)
Kerem, 2014 [21] 3
CFTR: at least one NS
Age: 6+
Sample size: 238
Ataluren TID
Placebo 48 weeks
(1) no significant change in ppFEV1
(2) no significant reduction in PEx rate
(2) no significant change in ST and NPD
Eight patients discontinued the
study drug (3.4%)
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Table 1. Cont.
Author, Year Phase Study Population Arms Duration Results(1 = Primary Outcome; 2 = Key Secondary Outcomes)
Patients Who Interrupted the
Study Drug Due to AEs
Boyle, 2014 [22] 2
Cohort 1:
CFTR: F/F
Age: 18+
Sample size: 62
Cohort 2:
CFTR: F/F
Age: 18+
Sample size: 82
CFTR:
F/any mutation
Age: 18+
Sample size: 27
Cohort 3:
CFTR: F/F
Age: 18+
Sample size: 15
Cohort 1:
LUM 200 mg SID/IVA 150 mg
BID
LUM 200 mg/IVA 250 mg BID
Placebo
Cohort 2, F/F:
LUM 200 mg SID/IVA 250 mg
BID
LUM 400 mg SID/IVA 250 mg
BID
LUM 600 mg SID/IVA 250 mg
BID
Placebo
Cohort 2, F/any mutation:
LUM 600 mg/IVA 250 mg
Placebo
Cohort 3:
LUM 400 mg BID/IVA 250 mg
BID
14 days of LUM followed by
7 days of LUM/IVA or
Placebo 21 days
28 days of LUM followed by
28 days of LUM/IVA
Placebo for 56 days
28 days of LUM followed by
28 days of LUM/IVA
Placebo for 28 days
28 days of LUM followed by
28 days of LUM/IVA
Placebo for 56 days
Cohort 1:
(1) ST: −12.6 (−17.2, −7.9) for IVA 250
mg vs. day 1
−10.9 (−17.6, −4.2) for IVA 250
mg vs. placebo
(1) Safety: no difference in AEs between groups
(2) absolute change in ppFEV1 at days 7, 14, and 21: not significant change in
LUM, LUM/IVA 250; 3.1 (0.1–6.1) in LUM/IVA 150 at day 21
(2) ST at day 14: data not presented
(2) PK: data not presented
Cohort 2:
(1) ST: −9.1 (−13.3, −4.9) in LUM 400 SID
−8.9 (−13.1, −4.7) in LUM 600
(1) Safety: no difference in AEs between groups
(2) absolute change in ppFEV1 at days 14, 28, 42, and 56: not significant
change in LUM; 6.2 (3.3–9) in LUM 600/IVA
2) ST at days 28 and 56: data not presented
2) CFQ-R at days 14, 28, 42, and 56: 15.9 (5.8, 26) in LUM 200; 13.5 (3.2, 23.9)
in LUM 400
(2) PK: data not presented
Cohort 3:
(1) ST: −10.3 (−16.7, −4)
(1) Safety: no difference in AEs between groups
(2) absolute change in ppFEV1 at days 14, 28, 42, and 56: 6.1 (2, 10.2) in LUM
400 BID/IVA 259 BID
(2) ST at days 28 and 56: data not presented
(2) CFQ-R at days 14, 28, 42, and 56: data not presented
(2) PK: data not presented
No discontinuations due to AEs
De Boeck, 2014 [23] 3
CFTR: at least one
non-G551D gating
mutation
Age: 6+
Sample size: 39
IVA 150 mg BID
Placebo 8 weeks
(1) absolute change in ppFEV1: 8.3 (4.5, 12.1)
(2) BMI: 0.7 kg/m2 (0.34, 0.99)
(2) ST: −49.2 (−57, −41.4)
(2) CFQ-R: 9.6 (4.5,14.7)
No discontinuations due to AEs
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Table 1. Cont.
Author, Year Phase Study Population Arms Duration Results(1 = Primary Outcome; 2 = Key Secondary Outcomes)
Patients Who Interrupted the
Study Drug Due to AEs
Wainwrigth, 2015 [9] 3
CFTR: F/F
Age: 12+
Sample size: 1108 (549 in
the TRAFFIC study and
559 in the TRANSPORT
study)
LUM 600 mg SID/IVA 250 mg
BID
LUM 400 mg BID/IVA 250 mg
BID
Placebo
24 weeks
(1) absolute change in ppFEV1: 2.8 (1.8, 3.8)
(2) relative change in ppFEV1: 4.8 (3.0, 6.6)
(2) BMI: 0.24 (0.11, 0.37)
(2) CFQ-R: 2.2 (0.0, 4.5)
(2) PEx: 0.39 (0.49, 0.76
In total, 31 patients discontinued
the study drug for elevation of the
creatine kinase level in four
patients, hemoptysis in three
patients, bronchospasm in two
patients, dyspnea in two patients,
pulmonary exacerbation in two
patients, and rash in two patients
(2.8%)
Moss, 2015 [24] 3
CFTR: at least one R117H
Age: 6+
Sample size: 69
IVA 150 mg BID
Placebo 24 weeks
(1) absolute change ppFEV1: 2.1 (1.13, 5.35)
2) ST: −24.0 mmol/L (−28.0, −19.9)
(2) CFQ-R: 8.4 (2.2–14.6)
No discontinuations due to AEs
Rowe, 2017 [25] 2
CFTR: F/ unresponsive to
ivacaftor CFTR mutation
Age: 18+
Sample size: 126
LUM 400 mg BID/IVA 150 mg
BID
Placebo
56 days
(1) absolute change in ppFEV1: no significant change
(2) no significant change in CFQ-R
(2) no change in BMI
(2) no change in FEV1
Four patients discontinued the
study drug for respiratory related
AEs (3.2%)
Taylor-Cousar, 2017
[14] 3
CFTR: F/F
Age: 12+
Sample size: 504
TEZ/IVA 100 mg SID/150 mg
BID
Placebo
24 weeks
(1) absolute change in ppFEV1: 4.0% (3.1, 4.8)
(2) relative change in ppFEV1: 6.8% (5.3, 8.3)
(2) CFQ-R: 5.1 points (3.2–7.0)
(2) decrease in PEx: −35%
(2) no difference in BMI
No discontinuations due to AEs
Ratjen, 2017 [26] 3
CFTR: F/F
Age: 6–11 years
Sample size: 206
LUM 200 mg BID/IVA 250 mg
BID
Placebo
24 weeks
(1) absolute change in LCI2.5 from baseline: −1.01 (−1·27, −0.75)
(2) ST: −20.8 (−23.4, −18.2)
(2) BMI: 0.38 (0.25, 0.52)
(2) CFQ-R: not significant change
(2) ppFEV1: not significant change
Two patients discontinued the
study drug for elevated liver
enzymes in one patient, rash in
one patient (1%)
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Table 1. Cont.
Author, Year Phase Study Population Arms Duration Results(1 = Primary Outcome; 2 = Key Secondary Outcomes)
Patients Who Interrupted the
Study Drug Due to AEs
Rowe, 2017 [10] 3
CFTR: F/RF
Age: 12+
Sample size: 246
TEZ 100 mg SID/IVA 150 mg
BID
IVA 150 mg BID
Placebo
Two treatment periods of 8
weeks separated by a
washout period of 8 weeks
(1) absolute change in ppFEV1 at average of weeks 4 and 8:
TEZ/IVA vs. placebo: 6.8 (5.7, 7.8)
IVA vs. placebo: 4.7 (3.7, 5.8)
TEZ/IVA vs. IVA: 2.1 (1.2, 2.9)
(2) absolute change in CFQ-R at average of weeks 4 and 8:
TEZ/IVA vs. placebo: 11.1 (8.7, 13.6)
IVA vs. placebo: 9.7 (7.2, 12.2)
TEZ/IVA vs. IVA: 1.4 (−1, 3.9)
(2) safety and tolerability:
(2) relative change in ppFEV1 at average of weeks 4 and 8:
TEZ/IVA vs. placebo: 11.4 (9.6, 13.2)
IVA vs. placebo: 8.1 (6.3, 9.9)
TEZ/IVA vs. IVA: 3.3 (1.8, 4.8)
(2) absolute change in ST at average of weeks 4 and 8:
TEZ/IVA vs. placebo: −9.5 (−11.7, −7.3)
IVA vs. placebo: −4.5 (−6.7, −2.3)
TEZ/IVA vs. IVA: −5.1 (−7, −3.1)
No discontinuations due to AEs in
the study group
Davies, 2018 [11] 2
CFTR: F/MF
Age: 18+
Sample size: 88
CFTR: F/F
Age: 18+
Sample size: 29
F/MF:
VX-659 80 mg SID/TEZ 100 mg
SID/IVA 150 mg BID
VX-659 240 mg SID/TEZ 100
mg SID/IVA 150 mg BID
VX-659 400 mg SID/TEZ 100
mg SID/IVA 150 mg BID
Placebo
VX-659/TEZ/VX-561* SID
Placebo
F/F:
VX-659 400 mg SID/TEZ 100
mg/IVA 150 mg BID
TEZ 100 mg SID/IVA 150 mg
BID
4 weeks followed by 4 days
of TEZ/IVA
4 weeks
4 weeks followed by 4 weeks
of TEZ/IVA
(1) safety and side-effects: not significant differences
(1) absolute change in ppFEV1 through day 29:
VX-659 80 mg: 10.2 (4.8, 15.5)
VX-659 240 mg: 12 (8, 16)
VX-659 400 mg: 13.3 (9.5, 17.1)
(2) absolute change in ST through day 29:
VX-659 80 mg: −45.7 (−54.4, −37)
VX-659 240 mg: −43.8 (−50.7, −37)
VX-659 400 mg: −51.4 (−57.8, −44.9)
(2) absolute change in CFQ-R at day 29:
VX-659 80 mg: 24.6 (13, 36.2)
VX-659 240 mg: 19.8 (11, 28.6)
VX-659 400 mg: 21.8 (13.6, 30)
(1) safety and side-effects: not significant differences
(1) absolute change in ppFEV1 through day 29: 12.2 (8.3, 16.2)
(2) absolute change in ST through day 29: −38.1 (−44.4, −31.8)
(2) absolute change in CFQ-R at day 29: 14.7 (7.1, 22.4)
(1) safety and side-effects: not significant differences
(1) absolute change in ppFEV1 through day 29: 9.7 (6.6, 12.7)
(2) absolute change in ST through day 29: −42.2 (−46.8, −37.7)
(2) absolute change in CFQ-R at day 29: 19.5 (13.1, 25.9)
No discontinuations due to AEs
Two patients discontinued the
study drug
No discontinuations due to AEs
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Table 1. Cont.
Author, Year Phase Study Population Arms Duration Results(1 = Primary Outcome; 2 = Key Secondary Outcomes)
Patients Who Interrupted the
Study Drug Due to AEs
Donaldson, 2018 [27] 2
CFTR: F/F
Age: 18+
Sample size: 131
CFTR: F/F
Age: 18+
Sample size: 67
CFTR: F/G551D
Age: 12+
Sample size: 18
Dose escalation:
TEZ 10 mg SID
TEZ 30 mg SID
TEZ 100 mg SID
TEZ 150 mg SID
TEZ 10 mg SID/IVA 150 mg
BID
TEZ 30 mg SID/IVA 150 mg
BID
TEZ 100 mg SID/IVA 150 mg
BID
TEZ 150 mg SID/IVA 150 mg
BID
Placebo
Dosage regimen testing:
TEZ 100 mg SID/IVA 150 mg
BID
TEZ 10 mg SID/IVA 50 mg BID
TEZ 50 mg SID/IVA 150 mg
BID
Placebo
TEZ 100 mg SID/IVA 150 mg
BID
Placebo/IVA 150 mg BID
28 days of treatment
28 days of washout
28 days of treatment
28 days of washout
28 days of treatment
28 days of washout
(1) safety through day 56: not significant between the groups
(1) change in ST through day 28: the highest reduction was reported in TEZ
100 mg: −19.58 (−24.57, −14.59)
(2) absolute change in ppFEV1 through day 28: the highest improvement
was reported in TEZ 100 mg/IVA 150 mg: 3.89 (0.94, 6.83)
(2) relative change in ppFEV1 through day 28: the highest improvement was
reported in TEZ 100 mg/IVA 150 mg: 7.04 (1.77, 12.31)
(1) safety through day 56: not significant between what was reported in TEZ
50 mg/IVA 150 mg: 1.02 (−6.04, 8.08)
(1) safety through day 56: not significant between the groups.
(1) change in ST through day 28: -17.2 (−31.75, −2.65)
(2) absolute change in ppFEV1 through day 28: 3.2 (−4.1, 10.51)
(2) relative change in ppFEV1 through day 28: 3.72 (−7.77, 15.21)
Four patients discontinued the
study drug
One patient discontinued the
study drug
No discontinuations due to AEs
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Table 1. Cont.
Author, Year Phase Study Population Arms Duration Results(1 = Primary Outcome; 2 = Key Secondary Outcomes)
Patients Who Interrupted the
Study Drug Due to AEs
Keating, 2018 [12] 2
CFTR: F/MF
Age: 18+
Sample size: 95
CFTR: F/F
Age: 18+
Sample size: 28
F/MF
ELX 50 mg SID/TEZ 100 mg
SID/IVA 150 mg BID
ELX 100 mg SID/TEZ 100 mg
SID/IVA 150 mg BID
ELX 200 mg SID/TEZ 100 mg
SID/IVA 150 mg BID
ELX 200 mg SID/TEZ 100 mg
SID/VX-561 * SID
Placebo
F/F
ELX 200 mg SID/TEZ 100 mg
SID/IVA 150 mg BID
TEZ 100 mg SID/IVA 150 mg
BID
4 weeks
F/MF
(1) absolute change in ppFEV1: 13.8 (10.9, 16.6)
(2) ST: −39.1 mmol/L (−44.9, −33.3)
(2) 25.7 points (18.3, 33.1)
FF
(1) absolute change in ppFEV1: 11.0 (7.9, 14.0)
(2) ST: −39.6 mmol/L (−45.3, −33.8)
(2) CFQ-R: 20.7 points (12.5, 29.0)
Three patients discontinued the
study drug (rash in one patient,
elevated bilirubin level in none
patient, and chest pain in one
patient)
Walker, 2019 [28] 3
CFTR: F/MF + F/F
Age: 6–11
Sample size: 13 (part A) +
70 (part B)
TEZ 50 mg SID/IVA 75 mg BID
TEZ 75 mg SID/IVA 150 mg
BID
24 weeks
(1) safety: no difference in AEs between groups in part A and B
(2) absolute change ppFEV1: 0.9 (−0.6, 2.3)
(2) relative change ppFEV1: 1.4 (−0.4, 3.1)
(2) increase in BMI: 0.23 (0.06, 0.40)
(2) ST: -14.5 (−17.4, −11.6)
(2) CFQ-R: 3.4 (1.4, 5.5)
No discontinuations due to AEs
Middleton, 2019 [13] 3
CFTR: F/MF
Age: 12+
Sample size: 403
ELX 200 mg SID/TEZ 100 mg
SID/IVA 150 mg BID
Placebo
24 weeks
(1) absolute change in ppFEV1 at week 4: 13.8 (12.1, 15.4)
(2) absolute change in ppFEV1 through week 24: 14.3 (12.7, 15.8)
(2) decrease in PEx through week 24: 0.37 (0.25, 0.55)
(2) absolute change in ST through week 24: −41.8 (−44.4, −39.3)
(2) absolute change in CFQ-R through week 24: 20.2 (17.5, 23)
(2) absolute change in BMI at week 24: 1.04 (0.85, 1.23)
(2) absolute change in ST at week 4: −41.2 (−44, −38.5)
(2) absolute change in CFQ-R at week 4: 20.1 (16.9, 23.2)
(2) time to first PEx through week 24: data not shown
(2) absolute change in BMI-for-age z score at week 24: data not shown
(2) absolute change in body weight at week 24: data not shown
Two patients discontinued the
study drug for rash in one patient,
portal hypertension in one patient
(0.5%)
Heijerman, 2019 [15] 3
CFTR: F/F
Age: 12+
Sample size: 107
ELX 200 mg SID/TEZ 100 mg
SID/IVA 150 mg BID
TEZ 100 mg SID/IVA 150 mg
BID
4 weeks
(1) absolute change in ppFEV1 at week 4: 10.4 (8.6, 12.2)
(2) absolute change in ST at week 4: −43.4 (−46.9, −40.0)
(2) absolute change in CFQ-R through week 4: 16.0 (12.1, 19.9)
No discontinuations due to AEs
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Table 1. Cont.
Author, Year Phase Study Population Arms Duration Results(1 = Primary Outcome; 2 = Key Secondary Outcomes)
Patients Who Interrupted the
Study Drug Due to AEs
Bell (I), 2019 [29] 2a
CFTR: F/F
Age: 18+
Sample size: 59
GLPG2222 50/100/200/400 mg
BID
Placebo
4 weeks
(1) safety
(2) decrease in ST: −15.8 mmol/L (−23.2, −8.3)
(2) change in ppFEV1: NS
(2) CFQ-R: NS
No discontinuations due to AEs
Bell (II), 2019 [29] 2a
CFTR: F/gating mutation
on IVA
Age: 18+
Sample size: 27
GLPG2222 150/300 mg BID
Placebo 4 weeks
(1) safety
(2) ST: -11.7 mmol/L (−21.1, −2.2)
(2) change in ppFEV1: NS
(2) CFQ-R: NS
No discontinuations due to AEs
Davies, 2019 [30] 2a
CFTR: at least one G551D
Age: 18+
Sample size: 26
One-week IVA washout
GLPG1837 increasing dose
Single-arm
4 weeks
(1) safety
(2) ST: −28.7 mmol/L (−39.1, −18.4)
(2) absolute change in ppFEV1: 4.6 (0.2, 5.3)
One patient interrupted the study
drug (non-cardiac increase in
CPK)
van
Konigsbruggen-Rietschel,
2019 [31]
2a
CFTR: F/F on LUM/IVA
Age: 18+
Sample size: 22
GLPG2737 25 mg BID + LUM
400 mg BID/IVA 150 mg BID
LUM 400 mg BID/IVA 150 mg
BID
4 weeks
(1) ST: −19.0 mmol/L (−36, −3.2)
(2) absolute change in ppFEV1: 3.4 (−0.5, 7.3)
CFQ-R: −1.1 (−2.1, 18.9)
No discontinuations due to AEs
Definitions: F = F508del CFTR mutation; RF = residual function mutation according to the trial list [10]; MF = minimal function CFTR mutation according to the trial list [12]; IVA =
ivacaftor; LUM = lumacaftor; TEZ = tezacaftor; ELX = elaxacaftor; PEX = pulmonary exacerbation; ST = sweat test; NDP: nasal potential difference; CFQ-RD = Cystic Fibrosis Questionnaire
Revised; SID = once daily; BID = twice daily. * a deuterated form of the CFTR potentiator ivacaftor.
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3.2. Primary and Secondary Outcomes
Analysis of outcome measures is reported in Table 1. Most studies assessed as primary outcome
the improvement in lung function, measured by the absolute change in ppFEV1 from baseline through
the study period (n = 13, 68%). A second group of studies, mainly phase 2 clinical trials, evaluated
safety and tolerability as their primary outcome (n = 7, 37%). Sweat chloride concentration and
number of pulmonary exacerbations (PEX) were the most prevalent secondary outcomes in 15 (79%)
and six (31%) studies, respectively. Patient-reported outcomes (PROs) were considered as primary
or secondary outcomes in 19 studies (83%). In all cases PROs were evaluated by the use of CFQ-R
Respiratory domain score.
3.3. Lung Function
Patients who had the most beneficial effects from CFTR modulators were those with one gating
mutation receiving IVA and those with p.Phe508del mutation, both homozygous and heterozygous,
receiving ELX/TEZ/IVA [8,13,15].
IVA 150 mg BID was associated with increase in ppFEV1 compared to placebo in patients
carrying p.Gly551Asp mutation, both aged 6–11 years (ppFEV1 +12.5 points) and ≥12 years (ppFEV1
+10.6 points) [8,20]. IVA increased lung function compared to placebo (ppFEV1 +8.3 points) in patients
aged ≥6 years carrying non-p.Gly551Asp gating mutations [23]. IVA was also reported to improve
ppFEV1 (+2.1 points) in patients ≥6 years with R117H [24].
Treatments with IVA alone and LUM alone were not effective on lung function in p.Phe508del
homozygous patients in two different phase 2 clinical trials, while the LUM/IVA association increased
ppFEV1 in both phase 2 and phase 3 trials in patients homozygous for p.Phe508del (+6.1 and +4.8 points,
respectively) [9,18,19,22].
TEZ/IVA significantly improved FEV1 in patients ≥12 years both p.Phe508del homozygous and
p.Phe508del along with a residual function mutation in comparison to placebo (ppFEV1 +4.0 and
+6.8 points, respectively) [10,14]. In this last study group, TEZ/IVA was associated with ppFEV1
improvement of 2.1 points compared to IVA alone [10]. No change in FEV1 was described for TEZ
alone in both populations [27].
Two triple combinations of either VX-659 or VX-445 (ELX) plus TEZ/IVA resulted in an overall
improvement in ppFEV1 compared to placebo in two phase 2 clinical trials recruiting patients≥12 years
both p.Phe508del homozygous (9.7 and 11.0 points, respectively) and p.Phe508del along with a minimal
function mutation (13.3 and 13.8 points, respectively) [11,12]. Treatment with ELX/TEZ/IVA confirmed
significant improvements of lung function in the same patient populations with ppFEV1 increase over
baseline of 10.4 and 13.8, respectively [13,15].
Referring to other genetic subsets, ataluren did not lead to any significant change in ppFEV1 in a
population of patients aged 6 years or more carrying at least one non-sense mutation [21].
Change in Lung Clearance Index (LCI) was also considered as primary outcome by one single
clinical trial [26]. Treatment with LUM/IVA demonstrated a slight but significant improvement in lung
ventilation measured as change of LCI 2.5 from baseline (−1.09 units) compared to placebo in patients
homozygous for p.Phe508del and aged 6–11 years.
3.4. Pulmonary Exacerbation
IVA demonstrated a 55% reduction in the risk of pulmonary exacerbation compared to placebo in
patients≥12 years receiving p.Gly551Asp [8]. The combination of LUM/IVA in patients homozygous for
p.Phe508del decreased both PEX and PEX conditioning hospitalization of 39% and 61%, respectively [9].
Lower annualized rate of pulmonary exacerbations in comparison to placebo was also demonstrated
for p.Phe508del homozygotes receiving TEZ/IVA (−35%) and ELX/TEZ/IVA (−63%) [14,15].
On the contrary, ataluren did not result in significant reduction of PEX episodes compared to
placebo for patients with at least one non-sense mutation in a phase 3 clinical trial [21].
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3.5. Sweat Chloride
Sweat chloride concentration was a relatively common secondary outcome in trials evaluating
CFTR modulators. The greatest improvement in sweat chloride was described in patients carrying
one gating mutation receiving IVA (48.1 mmol/L in p.Gly551Asp and 49.2 mmol/L in other gating
mutations) and those with p.Phe508del mutation, both homozygous and heterozygous, receiving
ELX/TEZ/IVA (43.4 mmol/L in homozygotes and 41.2 mmol/L in heterozygotes) [8,13,15,23].
Significant decreases in sweat chloride concentrations were described for p.Phe508del homozygous
patients with both the corrector ABBV-2222 (formerly GLPG2222) alone and the potentiator GLPG2737
on top of LUM/IVA (−15.8 and −11.7 mmol/L, respectively) [29,31]; and for p.Gly551Asp patients with
the potentiator GLPG1837 after IVA wash-out (−28.8 mmol/L) [30].
3.6. Patient-Reported Outcomes
Patients homozygous for p.Phe508del and patients with p.Phe508del and a minimal function
mutation in trans receiving ELX/TEZ/IVA had the most significant improvements on quality of life
in terms of CFQ-R Respiratory domain improvement (20.7 and 25.7 points compared to placebo,
respectively) [13,15].
Compared to placebo, IVA improved quality of life with similar magnitude in three different
groups: patients with p.Gly551Asp, patients with gating mutations other-than-p.Gly551Asp, and
patients with p.Arg117His mutation (8.6, 9.6, and 8.4 points in CFQ-R, respectively) [8,23,24]. Treatment
with TEZ/IVA was associated with CFQ-R increase of 11.1 points in patients with a residual function
mutation and 5.1 points in p.Phe508del homozygotes [10,14]. Significant but lower improvements in
CFQ-R were reported for patients receiving LUM/IVA (2.2 points) [9]. There was no improvement in
CFQ-R Respiratory domain score in comparison to placebo for p.Phe508del homozygous patients on
IVA and for patients aged 6–11 years on LUM/IVA [18,26]. Furthermore, ABBV-2222 on top of IVA in
patients with one gating mutation and GLPG2737 on top of LUM/IVA in patients homozygous for
p.Phe508del did not lead to increase in CFQR-R compared to placebo [29,31].
3.7. Safety
The highest rate of study drug discontinuation was reported during treatment with ataluren in
patients carrying a non-sense mutation (3.4%) [21]. Patients homozygous for p.Phe508del and treated
with LUM/IVA experienced drug discontinuation in 2.8% of study cohort resulting as the highest
discontinuation rate among CFTR modulators approved for clinical use [9]. The most frequent adverse
events were respiratory events including PEX, increase in cough or expectoration, upper respiratory
tract infections, or hemoptysis.
Regarding extra-respiratory events, headache and diarrhea were the most reported.
Table 2 summarizes the 15 most common adverse events across studies involving the four CFT
modulators currently available in clinical practice.
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Table 2. Cumulative incidence of 15 most common adverse events among the four CFTR modulators
currently available in clinical practice.
Event IVA (n = 483) LUM-IVA (n = 1111) TEZ-IVA (n = 607) ELX-TEZ-IVA (n = 276)
Number of Patients (Percent)
PEX 104 (21.5%) 355 (31.9%) 137 (22.6%) 59 (21.4%)
Cough 102 (21.1%) 224 (20.2%) 134 (22.1%) 57 (20.6%)
Oropharyngeal pain 46 (9.5%) 94 (8.5%) 31 (5.1%) 20 (7.2%)
Increased sputum 44 (9.1%) 166 (14.9%) 62 (10.2%) 60 (21.7%)
Nasal congestion 43 (8.9%) 82 (7.4%) 16 (2.6%) 0
Headache 44 (9.1%) 140 (12.6%) 79 (13%) 35 (12.7%)
Upper respiratory tract
infection 43 (8.9%) 78 (7%) 0 24 (8.7%)
Hemoptysis 26 (5.7%) 121 (10.9%) 38 (6.3%) 11 (4%)
Dyspnea 4 (0.8%) 126 (11.3%) 9 (1.5%) 0
Chest tightness 0 104 (9.4%) 0 0
Abdominal pain 34 (7%) 28 (2.5%) 10 (1.6%) 0
Fatigue 34 (7%) 9 (0.8%) 35 (5.8%) 9 (3.2%)
Pyrexia 34 (7%) 30 (2.7%) 50 (8.2%) 9 (3.2%)
Diarrhea 29 (6%) 99 (8.9%) 19 (3.1%) 26 (9.4%)
Increased AST or ALT > 3
ULN or increased
bilirubin > 1.5 ULN
39 (8.1%) 81 (7.3%) 29 (4.8%) 54 (19.6%)
Definitions: PEX: pulmonary exacerbations; ULN: upper level of normality.
4. Discussion
To the best of our knowledge, this is the most inclusive systematic review on efficacy and safety
of CFTR modulators in people with CF, including also data from recent clinical trials on the triple
combination therapy [32].
4.1. Expansion of the Target Population
Clinical studies on CFTR modulators span over a period of about 10 years, with a gradual
enlargement of the genotypes reached by the trials. While in the 2010–2013 period several studies
focused on IVA in patients carrying p.Gly551Asp, later the most tested compounds were LUM/IVA and
TEZ/IVA in individuals with p.Phe508del/p.Phe508del or p.Phe508del/any genotypes, that together
account for up to 85% of the affected alleles in North America and Europe [33].
A further expansion of the therapeutic indications of these compounds took place along three
main research paths. First, testing the highly effective IVA in patients carrying mutations sharing the
same class 3 functional classification as p.Gly551Asp or preserving some residual function. That was
the case for IVA, that was demonstrated effective in patients carrying non-Gly551Asp gating mutations
or the p.Arg117His mutation [23,24]. In 2017, FDA approved the extension of the use of IVA to treat
additional CFTR mutations based on results from an in vitro cell-based model system [34].
Second, CFTR modulators previously tested for safety and efficacy in adults were examined in a
subset of the pediatric population, as in the case of Davies and Ratjen, who tested IVA and LUM/IVA
in 6–11 years old children [20,26]. Only eight studies out of a total of 19 exclusively enrolled adults
(age 18+), while the majority involved a mixed population of adolescents, younger adults, and adults
with CF (age 12+). Overall, a total of 11 studies, that is a slight majority, involved groups of patients
with age <18 years old.
Finally, randomized controlled trials (RCTs) have been carried out to examine new molecules
and combinations [10–12,14]. Following the controversial clinical effects of lumacaftor (LUM),
additional research through high-throughput screening has been performed to identify next-generation
correctors [35]. To date, TEZ and ELX demonstrated the best pharmacological properties and clinical
efficacy in rescuing p.Phe508del CFTR. ELX in particular allowed to target new CF subpopulations
including those carrying p.Phe508del and either residual or minimal function mutations.
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4.2. Efficacy on Lung Function
Before the triple combination became available, of all CF genotypes it was IVA in patients with
p.Gly551Asp who reached the best primary endpoint results in a clinical trial [8]. Long-term treatment
with IVA in patients with gating mutations has been also associated with significant decrease in
mortality and in need for lung transplantation [36].
The degree of lung function and PEX improvement in p.Gly551Asp patients receiving IVA has
been for a few years the unapproachable benchmark and considered the only highly effective CFTR
modulator [8]. Recently, the triple combination in p.Phe508del homozygotes and in p.Phe508del
heterozygotes whose second mutation has minimal function showed clinical benefits of a magnitude
similar to those of p.Gly551Asp treated with IVA. In fact, the latter group of patients in the phase 3
clinical trial achieved a 10.6 increase in ppFEV1 compared to placebo, and patients with two or one
copy of p.Phe508del treated with ELX/TEZ/IVA experienced similar gains in ppFEV1, of 10.0 and
14.3, respectively [8,13,15]. These results acquire a particularly valuable clinical meaning considering
that before triple combination patients homozygous for p.Phe508del and treated with LUM/IVA
(6+ years old) or TEZ/IVA (12+ years old) had much smaller increases in lung function (2.8 and 4
percentage points, respectively) in comparison to placebo [9,14].
In relation to residual function genotypes, the phase 3 study EXPAND showed an increase
in ppFEV1 of 6.8 percentage points for patients with p.Phe508del in trans with a residual function
mutation and treated with TEZ/IVA [10]. The ongoing study of ELX in association with TEZ and IVA in
subjects with p.Phe508del and a gating or residual function mutation will confirm whether or not triple
combination could be extended even to patients already treated with an effective CFTR modulator
therapy (https://clinicaltrials.gov/, NCT04058353).
Although ivacaftor has demonstrated efficacy in achieving relevant clinical endpoints, it should
also be noted that an effort to develop better CFTR potentiators is underway. These potential new
treatments have shown promising results in clinical trials [29–31].
4.3. Efficacy on PEXs
The efficacy of CFTR modulators in PEX reduction was most relevant for p.Gly551Asp patients
treated with IVA (−55% PEX frequency) and p.Phe508del/minimal function patients treated with triple
combination (−63% PEX frequency) [8,15]. Although PEXs were not an efficacy outcome in the 4-week
trial of triple combination in p.Phe508del homozygotes, there was a decrease in respiratory-related
events in ELX/TEZ/IVA group compared with TEZ/IVA group [13,14]. Open-label extension studies
will explore the reproducibility of this outcome in patients with p.Phe508del homozygosity and over a
longer period of time.
4.4. Efficacy on Patient Reported Outcomes (PROs)
The magnitude of improvement in quality of life, and especially in the respiratory symptoms
domain, was in line with the increase in ppFEV1 across studies, thus confirming from a patient
perspective the clinical results.
4.5. Safety
Respiratory-related events were reported most frequently for LUM/IVA, which was also the
only compound associated with chest tightness. In 2017, Popowicz demonstrated that ppFEV1
acutely dropped of a mean of 19 percentage points (range −21% to –11%, p = 0.001) at 2 h after
LUM/IVA initiation in patients with p.Phe508del homozygosity and moderate to severe lung function
impairment [37]. These events are consistent with the relatively high number of patients who
discontinued LUM/IVA during RCTs or open label extended studies [9,38]. Some authors interpreted
chest tightness and bronchospasm as a marker of therapeutic efficacy, as mucus fluidification and
swelling following LUM/IVA administration might cause airway obstruction until phlegm is eventually
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expelled. However, a direct bronchospastic effect might be a more realistic explanation, in the light
that TEZ/IVA and the new triple combination therapy are better tolerated than LUM/IVA both in RCTs
and real life.
Abnormal liver function tests have been reported as common adverse events in patients treated
with CFTR modulators, both in children and adult populations; most of the events were low-to-moderate
in severity and did not require drug discontinuation.
ELX/TEZ/IVA combination therapy was also associated with skin rash, both in the p.Phe508del
homozygous and heterozygous study [13,15]. In the latter trial, the rash occurred in 22 patients (10.9%)
in the triple combination group and 13 patients (6.5%) in the placebo group. All events were defined as
low grade adverse events and resolved during the trial. Notably, in both trial groups rash was more
common in women receiving a concomitant hormonal oral contraceptive.
5. Unanswered Questions
The introduction of CFTR modulators in clinical practice has produced a significant impact on
short-term clinical outcomes in people with cystic fibrosis. However, high internal validity and strict
inclusion criteria in RCTs inevitably lead to low representativeness of everyday clinical practice.
An open question is if there are substantial effects in the severe patient subgroup that did not meet
lung function inclusion criteria and could not participate in the trials. Encouraging data come from a
recent cumulative analysis of outcomes from clinical trials, taking into consideration patients whose
ppFEV1 declined below 40 between screening and the randomization visit, and open-label extension
studies [39]. However, severity was merely defined as ppFEV1 <40 and did not fully represent the wide
range of real-life circumstances, like patients awaiting lung transplantation, continuous IV antibiotic
therapy, recurrent life-threatening hemoptysis, or NTM pulmonary disease.
On the other side, no data are available about the effects of CFTR modulators on people with very
mild or no pulmonary involvement. More evidence on this topic would be useful to clinicians in order
to guide the choice on the best timing to initiate CFTR modulators in the absence of respiratory disease.
Since ELX/TEZ/IVA proved to be a new highly effective treatment for people with p.Phe508del
mutation, many issues have been rising including its possible extension to treat rare mutations that
have currently no indications to CFTR modulators. Both translational experiments as well as further
understanding of the molecular basis of CFTR misfolding are now encouraged to answer this question.
A further question that lies unresolved is for how long clinical benefits secondary to CFTR
modulation can be maintained. A global evaluation of open-label extended studies and real life reports
from national registries might assess the long-term sustainability of the clinical benefits demonstrated
in RCTs and the overall impact not only on lung health but also extra-respiratory involvement,
co-morbidities, and mortality. Next steps should aim to systematize our comprehension of scientific
data of efficacy and safety coming from real life observational studies.
6. New Strategies beyond CFTR Potentiators and Correctors
The molecules included in this systematic review all belong to the two categories of potentiators
and correctors of CFTR protein along with their combinations. However, novel approaches to
post-translational modifications of CFTR protein are being explored in order to both address orphan
mutated alleles and optimize correction of p.Phe508del mutant protein. A complementary therapeutic
strategy is based upon the fact that the effectiveness of correctors and potentiators not only depends on
their potential to rescue CFTR function, but also on the quantity of protein to operate on. The assumption
is that augmenting the pool of CFTR available for modulation might translate into greater function
improvements. A recent high-throughput screening identified a new class of modulators acting
neither as potentiators nor correctors and termed amplifiers. These compounds have CFTR shown to
increase the expression of CFTR mRNA and immature CFTR protein across different CFTR classes
and mutations, including p.Phe508del [40]. Nesolicaftor (PTI-428, Proteostasis) is the first amplifier
tested both in vitro and in clinical trials. A study on HBE cell lines and patient-derived nasal cultures
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from Molinski and al. demonstrated a significantly higher increase in CFTR mRNA levels when the
combination of PTI-428 and LUM was used in comparison to LUM treatment alone [41]. A phase 2 trial
of nesolicaftor in combination with TEZ/IVA therapy in individuals with CF and homozygous for the
p.Phe508del mutation has been recently completed. Although PTI-428 did not reach the expected lung
function endpoint, the authors demonstrated an increase of approximately 50% in CFTR production
(NCT03591094) [42]. Nesolicaftor has also been studied in triple combination with two other CFTR
correctors, PTI-801 and PTI-808 (Proteostasis Therapeutics). The phase 2 study in patients with two
copies of the p.Phe508del mutation showed a significant 5 points increase in ppFEV1 (NCT03500263).
Proteostasis announced it will start two phase 3 clinical trials to follow up with the promising success
of this triple combination, in p.Phe508del homozygotes.
Another therapeutic approach aims at stabilizing the mutant CFTR protein which, after proper
trafficking to the cell surface, is already included in the membrane. The targets are variants
with reduced stability, like Class VI mutations or LUM-rescued p.Phe508del protein, where the
misfolding of the mutant protein prevented recycling and promoted lysosomal targeting and accelerated
endocytosis [43]. A novel class of CFTR modulators, named stabilizers, exerts its effect by targeting
conformation-dependent ubiquitines and other molecules involved in the peripheral quality control,
thus increasing half-life of the CFTR channel and preventing premature degradation [44]. Several
different molecules have demonstrated to improve CFTR stabilization, including the hepatocyte growth
factor (HGF), the vasoactive intestine peptide (VIP), and the inhibitors of S-nitrosoglutathione reductase
(GSNOR). Among them, cavosonstat (N91115, Nivalis Therapeutics) showed strong inhibitory activity
against GSNOR, thus preserving levels of S-nitrosoglutathione and positively affecting the stability of
CFTR [45]. The same compound together with CFTR correctors showed in vitro a significant increase in
the expression and activity of p.Phe508del [46]. In a recent phase 1 trial cavosonstat was well tolerated
and demonstrated significant reduction in sweat chloride when administered at the highest tested
dose [47]. However, in a series of two phase 2 trials cavosonstat combined with IVA and LUM/IVA did
not demonstrate significant effects on lung function (NCT02724527 and NCT02589236, respectively).
To the best of our knowledge, no further clinical development for cavosonstat is planned at this time.
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